1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Liver Failure (Hepatic Insufficiency) - Drugs In Development, 2022, provides an overview of the Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Liver failure is severe deterioration of liver function. Liver failure occurs when a large portion of the liver is damaged due to any type of liver disorder. Symptoms may include jaundice, tendency to bruise or bleed easily, ascites, impaired brain function (encephalopathy), poor weight gain and growth, fatigue, weakness, nausea and loss of appetite. Since these symptoms are associated with a host of other conditions, it may take some time before the correct diagnosis is made. As liver failure worsens, people may experience disorientation and drowsiness. At this stage, there is a risk of coma and death.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Liver Failure (Hepatic Insufficiency) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Liver Failure (Hepatic Insufficiency) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Liver Failure (Hepatic Insufficiency) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 4, 9, 17, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.
Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Liver Failure (Hepatic Insufficiency) (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Liver Failure (Hepatic Insufficiency) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Liver Failure (Hepatic Insufficiency) (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Liver Failure (Hepatic Insufficiency) (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Liver Failure (Hepatic Insufficiency) (Gastrointestinal)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Liver Failure (Hepatic Insufficiency) (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Liver Failure (Hepatic Insufficiency) - Overview
- Liver Failure (Hepatic Insufficiency) - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Liver Failure (Hepatic Insufficiency) - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Liver Failure (Hepatic Insufficiency) - Companies Involved in Therapeutics Development
- Liver Failure (Hepatic Insufficiency) - Drug Profiles
- Liver Failure (Hepatic Insufficiency) - Dormant Projects
- Liver Failure (Hepatic Insufficiency) - Discontinued Products
- Liver Failure (Hepatic Insufficiency) - Product Development Milestones
- Featured News & Press Releases
- Jun 24, 2022: Versantis presents new VS-01 data at The International Liver Congress 2022
- Nov 15, 2021: Versantis to present positive phase 1b data at AASLD for VS-01 in patients with decompensated Cirrhosis
- Nov 09, 2021: GENFIT announces first patient first visit for the evaluation of NTZ in subjects with hepatic impairment as part of its ACLF program
- Feb 01, 2021: Creative Medical Technology Holdings identifies and files patent on novel mechanism of ImmCelz therapeutic activity
- Jun 29, 2020: GoLiver Therapeutics receives a positive scientific advice from the European Medicines Agency (EMA) on its clinical development and biomanufacturing strategy for acute liver failure
- Jan 08, 2020: Promethera announces initiation of phase 2b DHELIVER study of HepaStem in patients with acute-on-chronic liver failure (ACLF)
- Dec 31, 2019: Versantis' main patent allowed in the USA.
- Nov 11, 2019: Promethera Biosciences presents updated clinical results at AASLD 2019 for world’s first stem cell therapy trial using HepaStem in acute-on-chronic liver failure
- May 09, 2019: Promethera Biosciences announces first-dosing in phase 2a clinical study evaluating world’s first liver stem cell therapy in late-stage NASH patients
- Apr 15, 2019: Promethera Biosciences presents updated Phase 2a results for world’s first stem cell clinical trial in ACLF at The International Liver Congress/ EASL 2019
- Mar 31, 2019: Versantis: Main patent for VS-01 granted in two additional countries.
- Mar 27, 2019: Promethera Biosciences announces late-breaking data presentation at EASL 2019 from World First Liver Stem Cell Clinical Trial in ACLF
- Mar 12, 2019: Promethera Biosciences to attend and present at upcoming scientific and partnering conferences in March and April
- Aug 29, 2018: cGMP Compliance Status for Promethera Biosciences’ Production Site in Durham, NC Confirmed by Health Canada
- Jul 17, 2017: Versantis Announces FDA Grants Orphan Drug Designation to VS-01 for the Treatment of Acute-on-Chronic Liver Failure
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- Number of Products under Development for Liver Failure (Hepatic Insufficiency), 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Liver Failure (Hepatic Insufficiency) - Dormant Projects, 2022
- Liver Failure (Hepatic Insufficiency) - Discontinued Products, 2022
- Number of Products under Development for Liver Failure (Hepatic Insufficiency), 2022
- Number of Products under Development by Companies, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Akaza Bioscience Ltd
- Arch Biopartners Inc
- Bopin (Shanghai) Biomedical Technology Co Ltd
- Bristol-Myers Squibb Co
- Cellaion SA
- Creative Medical Technology Holdings Inc
- EA Pharma Co Ltd
- Egetis Therapeutics AB
- Evive Biotech
- Galmed Pharmaceuticals Ltd
- Genesen Co Ltd
- Genfit SA
- GoLiver Therapeutics
- Grifols SA
- HepaRegeniX GmbH
- Immune Pharmaceuticals Inc
- iTolerance Inc
- Jiangsu Hengrui Medicine Co Ltd
- Mina Therapeutics Ltd
- Mitopower LLC
- Orgenesis Inc
- Pittsburgh ReLiver Inc
- PrimeGen Global Inc
- Proterris Inc
- Rejuvenation Technologies Inc
- SeaBeLife Spas
- Shiftbio Co Ltd
- SK Life Science Inc
- The Healthy Aging Co
- Tianjin Angsai Cell Genetic Engineering Co Ltd
- Unicyte AG
- Versantis AG
